MIAN
SUPN icon

Mariner Independent Advisor Network’s Supernus Pharmaceuticals SUPN Stock Holding History

Mariner Independent Advisor Network’s Portfolio SUPN Stock Details SUPN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-27,840
Closed -$871K – 317
2017
Q1 		$871K Buy
+27,840
New +$746K 0.11% 114

Other funds holding SUPN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
RHJA
Rice Hall James & Associates San Diego, California $1.8B AUM 36.16% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
RCAMU
Rothschild & Co Asset Management US Stamford, Connecticut $6.58B AUM 4.5% 1-Year Est. Return
RIM
Ranger Investment Management Dallas, Texas $1.38B AUM 24.55% 1-Year Est. Return

Mariner Independent Advisor Network's SUPN Position: Q2 2017 in Review

Mariner Independent Advisor Network sold out of Supernus Pharmaceuticals (SUPN) in Q2 2017, closing a stake of 27,840 shares — an estimated $871K sold.

Mariner Independent Advisor Network first reported a position in SUPN in Q1 2017 and held it in 1 quarter. The position peaked at $871K in Q1 2017. 265 funds tracked by Wall St. Rank hold SUPN as of Q2 2017.

  • Mariner Independent Advisor Network reported no remaining Supernus Pharmaceuticals position as of Q2 2017 after selling out during the quarter.
  • Mariner Independent Advisor Network sold 27,840 Supernus Pharmaceuticals shares in Q2 2017, an estimated $871K.
  • Mariner Independent Advisor Network first reported a position in Supernus Pharmaceuticals in Q1 2017 and held it in 1 quarter.
  • Mariner Independent Advisor Network's Supernus Pharmaceuticals position peaked at $871K in Q1 2017.
  • 265 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q2 2017.

Based on Mariner Independent Advisor Network's 13F filing for Q2 2017, filed 16 Aug 2017.